Breaking News Instant updates and real-time market news.

AVXS

AveXis

$47.51

2.35 (5.20%)

08:25
10/10/16
10/10
08:25
10/10/16
08:25

AveXis to host conference call

Conference call to discuss the AVXS-101 clinical update will be held on October 10 at 8:30 am. Webcast Link

  • 10

    Oct

  • 06

    Nov

AVXS AveXis
$47.51

2.35 (5.20%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.

TODAY'S FREE FLY STORIES

RTN

Raytheon

$155.27

-0.74 (-0.47%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Earnings
Raytheon reports Q1 EPS $1.73, consensus $1.61 »

Reports Q1 revenue $6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

SIRI

Sirius XM

$5.11

-0.095 (-1.83%)

07:01
04/27/17
04/27
07:01
04/27/17
07:01
Earnings
Sirius XM reports Q1 EPS 4c, consensus 4c »

Reports Q1 revenue $1.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 18

    May

AIT

Applied Industrial Technologies

$64.10

0.95 (1.50%)

07:01
04/27/17
04/27
07:01
04/27/17
07:01
Earnings
Applied Industrial Technologies reports Q3 EPS 75c, consensus 63c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 09

    May

BMY

Bristol-Myers

$53.77

-0.17 (-0.32%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Earnings
Bristol-Myers reports Q1 adjusted EPS 84c, consensus 74c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

ANTM

Anthem

$179.03

6.57 (3.81%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Upgrade
Anthem rating change  »

Anthem upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

SHOP

Shopify

$74.12

-2.53 (-3.30%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Downgrade
Shopify rating change  »

Shopify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 24

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Intelsat backs FY17 revenue view $2.18B-$2.23B, consensus $2.19B »

Backs FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Under Armour backs FY17 view for revenues growth of 11%-12% »

There are no changes to…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Intelsat reports Q1 EPS (29c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Under Armour reports Q1 EPS (1c), consensus (4c) »

Reports Q1 revenue…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
L3 Technologies raises FY17 EPS view to $8.50-$8.70 from $8.40-$8.60 »

FY17 consensus $8.60.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AB

AllianceBernstein

$22.75

-0.05 (-0.22%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
AllianceBernstein reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
WEX sees Q2 adjusted EPS $1.19-$1.26, consensus $1.30 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
Johnson Controls reports Q2 adj. EPS 49c, consensus 49c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
AstraZeneca confirms FY17 core EPS to decline low to mid teens percentage »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

WEX

WEX

$106.85

0.83 (0.78%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
WEX sees FY17 adjusted EPS $5.15-$5.50, consensus $5.33 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Park Sterling Bank »

Park Sterling Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

  • 25

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
L3 Technologies reports Q1 diluted cont ops EPS $2.07, consensus $1.81 »

Reports Q1 revenue $2.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
WEX reports Q1 adjusted EPS $1.23, consensus $1.22 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
AstraZeneca reports Q1 core EPS 99c vs. 95c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
Extended Stay lifts FY17 revenue view to $1.29B-$1.31B from $1.28B-$1.305B 

Consensus $1.3B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.